2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …
N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
AB van der Aart-van der Beek, RA de Boer… - Nature Reviews …, 2022 - nature.com
Chronic kidney disease (CKD) and heart failure affect many people worldwide. Despite the
availability of pharmacological treatments, both diseases remain associated with …
availability of pharmacological treatments, both diseases remain associated with …
Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape
CW Mende - Advances in therapy, 2022 - Springer
There is currently an unmet need for effective treatment of chronic kidney disease (CKD) that
slows disease progression, prevents development of end-stage kidney disease and …
slows disease progression, prevents development of end-stage kidney disease and …
Hypertension management in patients with cardiovascular comorbidities
Arterial hypertension is a leading cause of death globally. Due to ageing, the rising
incidence of obesity, and socioeconomic and environmental changes, its incidence …
incidence of obesity, and socioeconomic and environmental changes, its incidence …
The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension
HL Kim, EM Lee, SY Ahn, K Kim, HC Kim, JH Kim… - Clinical …, 2023 - Springer
Hypertension is the leading cause of death in human being, which shows high prevalence
and associated complications that increase the mortality and morbidity. Controlling blood …
and associated complications that increase the mortality and morbidity. Controlling blood …
A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
T Sen, HJL Heerspink - Cell metabolism, 2021 - cell.com
Sodium glucose co-transporter (SGLT) 2 inhibitors reduce the risk of kidney failure in
patients with and without type 2 diabetes (T2D). Although the precise underlying …
patients with and without type 2 diabetes (T2D). Although the precise underlying …
Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure
Background Empagliflozin reduces the risk of cardiovascular death or heart failure (HF)
hospitalization in patients with reduced ejection fraction. Its interplay with systolic blood …
hospitalization in patients with reduced ejection fraction. Its interplay with systolic blood …
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
PK Judge, N Staplin, KJ Mayne, C Wanner… - The Lancet Diabetes & …, 2024 - thelancet.com
Summary Background The EMPA-KIDNEY trial showed that empagliflozin reduced the risk
of the primary composite outcome of kidney disease progression or cardiovascular death in …
of the primary composite outcome of kidney disease progression or cardiovascular death in …
[PDF][PDF] Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
BACKGROUND: Chronic kidney disease (CKD) is associated with fluid excess which can be
estimated by bioimpedance spectroscopy. We aimed to assess effects of sodium glucose co …
estimated by bioimpedance spectroscopy. We aimed to assess effects of sodium glucose co …
Are SGLT2 inhibitors new hypertension drugs?
K Kario, KC Ferdinand, W Vongpatanasin - Circulation, 2021 - Am Heart Assoc
EDITORIAL for this finding is unclear, but this population is more likely to be older, to be
Black, and to be prescribed calcium channel blockers or β-blockers. It is possible that a lack …
Black, and to be prescribed calcium channel blockers or β-blockers. It is possible that a lack …